HeartBeam Reports Strong Q2 2024 Results and Advances Telehealth Diagnostic Technology

Financial Performance and Cash Position

HeartBeam, Inc. (NASDAQ: BEAT) reported its second quarter 2024 financial results, demonstrating a solid financial position. The company ended the quarter with $7.5 million in cash and cash equivalents, showing prudent cash management 1

1

. This financial stability provides HeartBeam with a runway to continue its operations and advance its innovative cardiac care solutions.

Progress on AIMIGo™ Device

One of the key highlights of HeartBeam's Q2 performance was the significant progress made on its AIMIGo™ device. This credit card-sized diagnostic device is designed to provide a 3D vector ECG recording of a patient's heart 2

2

. The company reported that it has successfully completed the AIMIGo™ device's development and is now moving forward with preparations for FDA submission, expected in the fourth quarter of 2024.

Advancements in AIMI™ Software Platform

HeartBeam also made notable strides with its AIMI™ (AI-powered Myocardial Infarction) software platform. This innovative solution is designed to assist in the diagnosis of heart attacks and other cardiac conditions. The company announced that it has initiated the limited market release of the AIMI™ software, focusing on emergency department settings 1

1

. This strategic move allows HeartBeam to gather real-world data and feedback, which will be crucial for future enhancements and wider adoption.

Expansion of Intellectual Property Portfolio

During the second quarter, HeartBeam continued to strengthen its intellectual property position. The company was granted two new patents, bringing its total patent portfolio to 11 issued US patents 2

2

. These patents further protect HeartBeam's innovative technologies and solidify its position in the telehealth cardiac care market.

Strategic Partnerships and Market Positioning

HeartBeam's management emphasized the company's focus on establishing strategic partnerships to enhance its market position. The company is actively engaging with potential partners in the healthcare industry to explore opportunities for collaboration and integration of its technologies into existing healthcare ecosystems 1

1

. These efforts are aimed at accelerating the adoption of HeartBeam's solutions and expanding its reach in the telehealth market.

Future Outlook and Milestones

Looking ahead, HeartBeam outlined several key milestones for the remainder of 2024 and beyond. The company anticipates submitting its AIMIGo™ device for FDA clearance by the end of the year, which could potentially pave the way for commercialization in 2025 2

2

. Additionally, HeartBeam plans to expand the rollout of its AIMI™ software platform, targeting both emergency departments and telehealth providers.